Abstract
To prevent serious complications such as permanent loss of vision and structural vascular damage, treatment must be initiated quickly in patients with giant-cell arteritis (GCA). So far, usually long-term corticosteroids in cumulative high dosages have been the standard therapy option. However, steroids are often insufficient to achieve adequate disease control and are associated with serious adverse events. Therefore, steroid-sparing therapy options are the focus of interest.
| Translated title of the contribution | Actual Treatment Options for Giant Cell Arteritis |
|---|---|
| Original language | German |
| Journal | Deutsche Medizinische Wochenschrift |
| Volume | 144 |
| Issue number | 9 |
| Pages (from-to) | 595-600 |
| Number of pages | 6 |
| ISSN | 0012-0472 |
| DOIs | |
| Publication status | Published - 2019 |
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)